The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir

International Journal of STD and AIDS

Volumn 12, Issue 1, 2001, Pages 29-33

  Nouts, C ^a   Bonarek, M ^a   Morlat, P ^a   Delevaux, I ^a   Bonnet, F ^a   Lacoste, D ^a   Bernard, N ^a   Beylot, J ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Bilirubinaemia; HIV infection; Indinavir; Prognostic factors

Indexed keywords

INDINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERBILIRUBINEMIA; INDINAVIR; MALE; PROGNOSIS; TREATMENT FAILURE;

EID: 0035150316     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462011916703     Document Type: Article

References (10)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
4. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
5. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients
6. Treatment with indinavir, zidovudine, and lamivudine: Three-year follow-up
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
8. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
9. Protease inhibitors for the treatment of human immunodeficiency virus infection